Page 224 - HIV/AIDS Guidelines

OAR Office of AIDS Research

OARAC Office of AIDS Research Advisory Council
OI opportunistic infection
PAH pulmonary arterial hypertension
PCP Pneumocystis jirocevi pneumonia or Pneumocystis pneumonia

PDE5 phosphodiesterase type 5
PegIFN peginterferon
p-gp p-glycoprotein
PI protease inhibitor
PK pharmacokinetic
PMTCT prevention of mother-to-child transmission

PNS peripheral nervous system
PO by mouth
PPI proton pump inhibitor
PR protease (gene)

PT prothrombin time

QTc QT corrected for heart rate

RAL raltegravir
RBV ribavirin

RPV rilpivirine
RT reverse transcriptase (gene)
RT-PCR reverse transcriptase-polymerase chain reaction
RTV ritonavir

SJS Stevens-Johnson syndrome
soln solution
SPT skin patch test
SQV saquinavir
SQV/r saquinavir/ritonavir

STD sexually transmitted disease
SVR sustained virologic response

t ½ half-life

T20 enfuvirtide
tab tablet
TAM thymidine analogue mutation
TB tuberculosis

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents N-5

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.